This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
ARHGAP1 / Rho GTPase-activating protein 1 · IHC design guide
Design Immunohistochemistry for ARHGAP1
Plan chromogenic ARHGAP1 IHC around variable cytoplasmic tissue staining (HPA tissue IHC). Colon glandular cells provide a high staining reference, while adipocytes are reported as undetected (HPA tissue IHC); the catalog antibody lists an IHC dilution of 1:100–1:300 (datasheet).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
ARHGAP1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic in tissue sections (HPA tissue IHC) | |
| Staining pattern | Variable cytoplasmic staining in most tissues (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | Adipose tissue+1 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific); Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A06116) | |
| Caveat | Staining varies by tissue and cell type (HPA tissue IHC) | |
| Regulation | No specific regulator reported (UniProt) | |
| Isoform / epitope | No listed isoforms; one 1–439 chain (UniProt) |
Section 1
Recommended ARHGAP1 IHC & IF Protocols
The catalog antibody’s IHC-P protocol is accompanied by a published ARHGAP1 IHC protocol for mouse calvarial bone (PMC7900016).
| Sample | Paraffin-embedded human heart tissue; fixative not specified (datasheet A06116) |
| Fixation | Image fixative and duration unreported (datasheet A06116); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-ARHGAP1, 1:100 - 1:300 (datasheet A06116) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | ARHGAP1-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic expression at variable levels in most tissues. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6.0 HIER at 95–98 °C for 20 min (page retrieval rule); the published protocol does not specify retrieval (PMC7900016).
Section 2
What Is the Expected ARHGAP1 Staining Pattern?
ARHGAP1 is a cytoplasmic protein with no transmembrane segment (UniProt Q07960). In paraffin-section IHC, expect variable cytoplasmic staining across many tissues, including high staining in glandular and respiratory epithelial cells (HPA: tissue IHC). HPA rates the tissue staining profile Approved, with medium consistency between antibody staining and RNA expression; use its cell-level pattern as a guide rather than an absolute pass/fail threshold (HPA: tissue IHC).
| Cytoplasmic signal in breast or colon glandular cells, or bronchial respiratory epithelial cells (HPA: High in these cells). | This matches the reported compartment and high-staining cell types (UniProt Q07960; HPA: tissue IHC). Judge intensity against other cells on the same section and a matched negative control; variable staining across tissues is expected (HPA: tissue IHC; general IHC practice). |
| Predominantly nuclear staining, or a crisp plasma-membrane outline, with little cytoplasmic signal. | Treat this as a compartment mismatch requiring verification: UniProt places ARHGAP1 in the cytoplasm and lists no transmembrane segment (UniProt Q07960). Review the negative control, detection reagents and staining distribution before assigning the signal to ARHGAP1 (general IHC practice). |
| Strong staining in adipocytes or skeletal-muscle myocytes while expected epithelial cells show little signal. | HPA reports ARHGAP1 as not detected in those cell types and high in several epithelial cell types (HPA: tissue IHC). Investigate cross-reactivity or endogenous chromogenic detection activity; a single unexpected positive cell population does not establish either cause (general IHC practice). |
| Uniform color over cells, stroma and empty areas, obscuring cell boundaries. | A diffuse field cannot reliably establish the reported cytoplasmic pattern (HPA: tissue IHC; general IHC practice). Compare a section processed without primary antibody, then check blocking, washing and chromogen development for nonspecific or detection-related background (general IHC practice). |
| No cytoplasmic signal in a section containing breast or colon glandular cells. | Those cells are reported as High, so this is a useful prompt to check assay performance (HPA: tissue IHC). Confirm that the relevant cells are present and inspect retrieval, antibody concentration and detection controls; one negative section alone does not overturn the HPA profile (general IHC practice). |
💡Expected ARHGAP1 appearanceCall a result consistent when glandular or respiratory epithelial cells show clear, variably intense cytoplasmic staining (HPA: tissue IHC); dominant nuclear, membrane-outline or uniform background signal needs verification (UniProt Q07960; general IHC practice).
| Cell and tissue context | HPA reports variable cytoplasmic expression in most tissues, with High staining in the listed glandular and epithelial cells and no detection in adipocytes or skeletal-muscle myocytes (HPA: tissue IHC). Select and interpret controls at the cell level. |
| Protein location and topology | ARHGAP1 is cytoplasmic and has no transmembrane segment (UniProt Q07960). A membrane-outline pattern is therefore unsupported as the dominant IHC result; this record provides no antibody epitope location from which to choose a target-specific retrieval condition. |
| Antibody evidence | HPA lists IHC as Approved for HPA004689 and HPA008285, while its tissue profile has medium staining-versus-RNA consistency (HPA: antibodies; HPA: tissue IHC). Record which antibody produced a result and corroborate an unexpected pattern with suitable controls. |
| IF/ICC Q: What pattern is expected? | A: Mainly cytosol; vesicle localization is Approved, while primary-cilium localization is Uncertain (HPA: subcellular ICC-IF). Use that evidence to interpret IF/ICC images; it does not make vesicle or cilium staining a required paraffin IHC result. |
| Situation | Likely cause | Next action |
|---|---|---|
| Expected positive epithelial cells are unstained. | A failed staining run or insufficient assay sensitivity is possible; HPA reports High staining in breast and colon glandular cells and bronchial respiratory epithelial cells (HPA: tissue IHC). | Check section cell identity and a known-positive section, then review the IHC-validated antibody dilution, retrieval and detection steps using its supplied IHC-P instructions (general IHC practice). |
| The section shows mainly nuclear signal. | The dominant compartment conflicts with cytoplasmic localization (UniProt Q07960; HPA: tissue IHC). The record alone cannot identify the source of the nuclear signal. | Compare the no-primary control and an expected positive cell population; repeat or corroborate the pattern with an independently validated IHC antibody if available (general IHC practice). |
| Adipocytes or skeletal-muscle myocytes stain strongly. | HPA reports no detection in those cells (HPA: tissue IHC). Cross-reactivity or endogenous detection activity is possible, but neither is proven by appearance alone (general IHC practice). | Compare no-primary and detection-only controls, assess whether color follows the same cells, and verify an expected cytoplasmic positive population (general IHC practice). |
| Chromogen coats the section diffusely. | Broad background may reflect nonspecific binding, incomplete washing or overdevelopment (general IHC practice); it prevents a reliable comparison with the reported cytoplasmic pattern (HPA: tissue IHC). | Inspect the no-primary control, review blocking and washes, and adjust chromogen development according to the detection system's instructions (general IHC practice). |
| A positive tissue has patchy or weaker staining than expected. | HPA describes variable staining across most tissues and only medium consistency with RNA data (HPA: tissue IHC). Section composition or staining-run variation can also affect the comparison (general IHC practice). | Score the specified cell population, compare matched control sections in the same run, and document the fraction and intensity of cytoplasmic staining (general IHC practice). |
| IF/ICC shows vesicles or a primary cilium, but IHC does not. | Vesicle localization is Approved and primary-cilium localization is Uncertain in ICC-IF (HPA: subcellular ICC-IF). These observations do not set a required IHC-P pattern. | Interpret paraffin IHC against its cytoplasmic tissue profile and controls (HPA: tissue IHC; general IHC practice). Assess the subcellular IF/ICC question in its own guide. |
Experiment evidence
IHC & IF images showing ARHGAP1 staining
A06116 · IHCImmunohistochemistry analysis of paraffin-embedded human heart tissue, using RHG1 Antibody. The picture on the right is blocked with the syn
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000175220-ARHGAP1/tissue/cerebral+cortex#imid_1555040
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000175220-ARHGAP1/tissue/colon#imid_1554958
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000175220-ARHGAP1/tissue/liver#imid_1554967
HPA · PancreasHuman Protein Atlas IHC, Pancreas. Source: https://www.proteinatlas.org/ENSG00000175220-ARHGAP1/tissue/pancreas#imid_1554926
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA004689; green = ARHGAP1, blue = nucleus, red = microtubules.
HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody HPA004689; green = ARHGAP1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for ARHGAP1 IHC & IF
🧪Run colon first and require staining in its glandular cells (HPA: High in colon glandular cells). Use skeletal muscle myocytes as the negative tissue (HPA: Not detected in skeletal muscle myocytes); no cell population within the colon slide is established as ARHGAP1-negative by the supplied HPA rows, so treat non-glandular cells without cytoplasmic staining above background as internal negative observations, not confirmed biological negatives (HPA: colon glandular-cell row only; UniProt Q07960: ubiquitous, cytoplasmic).
Positive control tissue: Adrenal gland (Glandular cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show ARHGAP1 in A-431, U-251MG, U2OS, ASC52telo, RPTEC/TERT1, hTERT-RPE1 (serum starved), KOLF2.1J, with annotated localisation: Cytosol (supported) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control and an isotype control matched to the primary antibody’s host species and immunoglobulin class, with the appropriate clonality (standard IHC practice); use a knockout sample or cognate-peptide block as a biological specificity control (A06116 caption: peptide-blocked heart section). Quench endogenous peroxidase for chromogenic detection, and check endogenous biotin if using avidin–biotin detection (standard IHC practice).
⚠️Feasibility: No target-specific fixation window or fixation effect is reported in the supplied evidence; the A06116 paraffin-section heart caption does not state a fixative (A06116 caption: fixative unreported). Retrieval dependence is unreported, so optimize antigen retrieval empirically for IHC-P (supplied evidence: no retrieval condition; standard IHC practice). The supplied evidence does not establish that frozen sections or tissue IF are easier; inspect colon sections for nonspecific signal in mucus and luminal debris when scoring glandular cytoplasm (HPA: High in colon glandular cells; standard IHC practice).
HPA tissue IHC evidence for ARHGAP1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Breast | Glandular cells | High | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | High | Protein (IHC) | HPA → |
| Cervix | Glandular cells | High | Protein (IHC) | HPA → |
| Colon | Glandular cells | High | Protein (IHC) | HPA → |
Section 3
Advanced ARHGAP1 IHC Tips
Troubleshoot ARHGAP1 staining by checking retrieval, tissue handling, cytoplasmic localisation, controls and the cell population used for scoring.
How should I optimise antigen retrieval when ARHGAP1 staining is weak?
Start with citrate buffer at pH 6.0, 95–98 °C for 20 min on paraffin sections (page retrieval rule). Cool sections consistently before staining, and compare a known positive glandular region across retrieval runs; colon glandular cells show high staining (HPA: colon glandular cells, High). If signal remains weak, test an alkaline retrieval buffer at pH 9 as a fallback on adjacent sections (standard IHC practice). Keep antibody concentration and detection conditions constant during that comparison so changes in cytoplasmic signal can be attributed to retrieval (UniProt Q07960: cytoplasmic localisation; standard IHC practice).
Could fixation explain variable ARHGAP1 staining between paraffin blocks?
Target-specific fixation sensitivity is unknown: the selected A06116 paraffin-section caption identifies human heart but does not state its fixative (A06116 tissue-IHC caption). Record each block’s fixative and fixation duration, then compare blocks with similar processing and viable tissue rather than treating a staining difference as biological (standard IHC practice). For newly prepared material, use a consistent routine formalin fixation and processing schedule, and document any departures from it (standard IHC practice). Include the same positive control section in each run; high glandular-cell staining in colon offers a reference for assessing run-to-run variation (HPA: colon glandular cells, High).
What staining pattern should count as ARHGAP1 positive in tissue?
Score predominantly cytoplasmic staining in identifiable cells, since ARHGAP1 is cytoplasmic and has no transmembrane segment (UniProt Q07960: localisation and topology). The expected pattern can vary in intensity across tissues; the tissue profile reports variable cytoplasmic expression in most tissues (HPA: tissue IHC profile). Discrete vesicular or ciliary localisation has been reported by cellular imaging, but chromogenic tissue staining may not resolve those structures reliably (HPA: subcellular localisation; standard IHC practice). If the dominant signal is nuclear or confined to cell borders, review morphology and controls before calling it positive (UniProt Q07960: cytoplasmic localisation; standard IHC practice).
How do I assess epitope-dependent staining without a mapped antibody epitope?
Treat the antibody epitope as unmapped in this evidence set, and avoid assigning a staining pattern to a particular domain or modification (provided antibody evidence). The recorded protein has 439 residues, a CRAL-TRIO domain at residues 63–218, a Rho-GAP domain at 244–431, and 0 listed isoforms (UniProt Q07960). Several N-terminal serines are phosphorylated, but their effect on tissue staining is not established here (UniProt Q07960: modified residues). The selected A06116 heart image includes peptide-blocked staining; use that comparison as an epitope-competition check while retaining tissue and detection controls (A06116 tissue-IHC caption; standard IHC practice).
How should an IF experiment clarify ambiguous chromogenic ARHGAP1 staining?
In a separate IF/ICC experiment, pair ARHGAP1 with a marker that identifies the expected cell population; colon glandular cells are a high-staining example (HPA: colon glandular cells, High). Choose a spectrally separated, preferably far-red fluorophore when tissue autofluorescence obscures shorter wavelengths, and inspect single-channel and unstained controls (standard IF practice). Because ARHGAP1 is cytosolic and lacks a transmembrane segment, assess mild permeabilisation for access to the intracellular epitope, comparing treated and untreated material (UniProt Q07960: localisation and topology; standard IF practice). Use the IF result to assess cell identity and spatial distribution while keeping the chromogenic tissue score based on its own controls (standard IHC/IF practice).
How can I distinguish ARHGAP1 staining from chromogenic background?
Compare the test section with a no-primary control, and check whether diffuse colour persists in the same structures without primary antibody (standard IHC practice). For peroxidase detection, a 3% hydrogen peroxide block for about 10 min and appropriate protein blocking are general starting points, subject to tissue and detection-system requirements (standard IHC practice). Titrate the IHC-validated antibody against signal in a positive control rather than increasing detection strength to rescue weak staining; colon glandular cells stain highly (HPA: colon glandular cells, High; standard IHC practice). The selected A06116 human-heart image includes a peptide-blocked comparison, which can inform specificity assessment but does not replace no-primary or tissue controls (A06116 tissue-IHC caption; standard IHC practice).
What should I measure when comparing ARHGAP1 across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population before scoring and measure cytoplasmic staining within viable, morphologically identifiable cells (UniProt Q07960: cytoplasmic localisation; standard IHC practice). An H-score combines the percentages of cells at intensities 0–3 into a 0–300 score; report percentage positive separately when the staining threshold matters (standard IHC practice). Normalise counts to the number of eligible cells, or stained area to the eligible tissue area in mm², using the same rule across sections (standard IHC practice). Compare like cell populations because the tissue profile reports variable cytoplasmic levels, including high glandular-cell staining in colon (HPA: tissue IHC profile; HPA: colon glandular cells, High).
When should an apparent ARHGAP1 positive result be questioned?
Give greatest weight to cytoplasmic signal in intact, correctly identified cells, consistent with the recorded protein localisation and tissue staining profile (UniProt Q07960: cytoplasmic localisation; HPA: tissue IHC profile). High staining in colon glandular cells and undetected staining in adipocytes provide contrasting tissue references, although section processing and cell identity still need review (HPA: colon glandular cells, High; HPA: adipocytes, Not detected; standard IHC practice). Question colour concentrated at section edges, in necrotic regions, or in structures coloured by the no-primary control (standard IHC practice). Check peroxidase blocking and peptide competition where applicable before interpreting such colour as ARHGAP1 expression (A06116 tissue-IHC caption; standard IHC practice).
Boster reagents
Best ARHGAP1 / Rho GTPase-activating protein 1 IHC Antibodies
A06116 has real IHC data from paraffin-embedded human heart tissue (catalog image caption). IF/ICC is listed, with stated human and mouse reactivity (catalog); no IF figure is supplied (catalog).
Real IHC data
Anti-RHG1 ARHGAP1 Antibody
Cat # A06116
A06116 will render with an IHC image of paraffin-embedded human heart tissue and a peptide-blocked comparison (catalog image caption). It is listed for IHC, IF and ICC, with human and mouse reactivity (catalog applications and reactivity).
Which to pick: Choose A06116 for tissue IHC because its own image shows staining of paraffin-embedded human heart tissue (catalog image caption); the fixative is unreported (catalog image caption). For IF/ICC, A06116 is listed for both applications, but has no IF figure in the payload (catalog). For human or mouse samples, A06116 is the rabbit polyclonal option with stated reactivity to both species (catalog).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q07960 (RHG01_HUMAN, Rho GTPase-activating protein 1).
- Human Protein Atlas. ARHGAP1 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. ARHGAP1 subcellular location (ICC-IF): Mainly localized to the cytosol. In addition localized to vesicles and primary cilium..
- Human Protein Atlas. ARHGAP1 antibody validation summary (2 antibodies).
- Osteoclast-derived small extracellular vesicles induce osteogenic differentiation via inhibiting ARHGAP1. Molecular therapy. Nucleic acids 2021 — PMC7900016.
- PubMed PMID:8253717 — UniProt-cited evidence.
- PubMed PMID:8288572 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for ARHGAP1 (Rho GTPase-activating protein 1). Expected localisation Cytoplasmic in tissue sections (HPA tissue IHC). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: A06116 at 1:100 - 1:300 (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human heart tissue; fixative not specified (datasheet A06116); 2. Fixation: Image fixative and duration unreported (datasheet A06116); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-ARHGAP1, 1:100 - 1:300 (datasheet A06116); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A06116); Caveat: Staining varies by tissue and cell type (HPA tissue IHC); Isoform / epitope: No listed isoforms; one 1–439 chain (UniProt); Regulation: No specific regulator reported (UniProt). Evidence: UniProt Q07960, HPA tissue IHC · Approved, HPA ICC-IF · Mainly localized to the cytosol. In addition localized to vesicles…, Datasheet A06116, PMC7900016. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/ARHGAP1/immunohistochemistry-ihc-guide.